---
type: Phase Exit Review
title: TreatFlow 000-E — Intake Consolidation, Exit Decision and Phase 001 Handoff
description: Project-specific Phase 000 exit assessment and evidence-aware purpose-discovery handoff.
tags: [treatflow, phase-000, exit-review, phase-001, handoff]
---

# TreatFlow — 000-E Phase 000 Exit Review

## Decision

**PASS WITH CARRY-FORWARD — Phase 000 intake complete; Phase 001-A next eligible after merge.**

This is an intake exit, **not** proof of user demand, statistical validity, legal compliance, finalized concepts, implementation readiness, or production readiness. Inherited Base templates remain process guidance, not TreatFlow execution evidence.

## 1. Planned work and evidence

| Subphase | Evidence | Disposition |
|---|---|---|
| 000-A | [Project intake start gate](000-a-treatflow-execution.md) | Complete; intake sequence and evidence posture approved |
| 000-B | [Actors, product context and outcomes](000-b-treatflow-execution.md) | Complete; actors, affected nonparticipants and provisional outcomes distinguished |
| 000-C | [Observation and research sensitivities](000-c-treatflow-execution.md) | Complete; measurement/Poisson alternatives and privacy risks explicit |
| 000-D | [Scope and uncertainty disposition](000-d-treatflow-execution.md) | Complete; provisional boundaries, constraints and twelve assigned questions |
| 000-E | This review and current documentation corrections | Intake exit assessed; Phase 001 handoff recorded |

## 2. Intake coverage and exit classification

| Required dimension | Result | Basis / caveat |
|---|---|---|
| Contemplated product | Established | Crowdsourced Halloween arrival observation and research data |
| Motivating opportunity | Established with uncertainty | Sponsor's curiosity/participatory research intent; unmet demand unverified |
| Actors and affected parties | Established with uncertainty | Contributors, analysts, operator, households, visitors, minors and public; participation empirical details unknown |
| Intended outcomes | Established with uncertainty | Ease, interpretability, research, privacy, proportionality; Phase 001 may challenge |
| Scope and non-goals | Established with uncertainty | Small-scale experimental framing; web-first/adults/single-year remain proposals |
| Terminology | Established with uncertainty | Group versus visitor, observed versus missing time, event versus submission time; final observation semantics open |
| External constraints | Established with uncertainty | Privacy/safety/security risks identified; legal applicability and compliance not determined |
| Assumptions and hypotheses | Established | Explicit voluntary sampling concerns, candidate Poisson and non-Poisson explanations |
| Open questions | Established | 000-D Q-01–Q-12 with downstream destinations and prelaunch gates |
| Evidence/source posture | Established | Sponsor statements distinguished from inferences, hypotheses, risk scenarios and provisional proposals |
| Legacy/current-state context | Not applicable to product | No previous TreatFlow app; Base template inheritance assessed separately |

None of the remaining unknowns prevents **purpose discovery**. Several **do prevent launch** until the proper later work resolves them.

## 3. Evidence, contradiction and solution-lock audit

The product-specific foundation consists of sponsor statements and project analysis, not field measurements, interviews, validated user demand, published statistical conclusions or legal advice. No conflicting independent evidence is currently available; lack of evidence is not evidence of agreement. Repeated hypotheses are not promoted to facts.

The Poisson idea is a research question, not a required result; homogeneous rate, time-varying rates, dependence, reporting gaps and sampling biases remain possible. Group arrivals are not assumed equivalent to independent individual events. Non-reporting is not treated as an observed zero.

Candidate implementation choices—web/native, identity provider, database, reporting mode, data schema, geographic granularity, open versus gated export—remain explicitly undecided. The data-protection objective does not authorize a particular release policy or assert that pseudonyms provide anonymity.

## 4. Inherited Base authority and documentation audit

The historical Base methodology and refined phase contracts remain intentionally available. Their template preparation history, including Phase 012 self-audit, is **not** TreatFlow progress. The repository's current user-facing README, bundle index and agent entry instructions have been reoriented toward TreatFlow in this PR without rewriting historical Base contracts. Process authority stays in `docs/methodology/`; current product intake lives in [canonical project intake](../../canonical/project/intake.md); chronological decisions remain in Phase 000 records.

Structural checks within the scope of this review: Phase 000 and canonical navigation updated, new ordinary document declares an OKF `type`, indexes remain navigational, expected intake documents are present, and linked phase/canonical paths were verified against the repository file tree. This is a scoped structural/reference review, **not** a runtime test or certification that every inherited template link throughout all 87 files is valid.

No source code, executable test harness, schema or infrastructure was present in the reviewed main repository tree; this PR only changes documentation.

## 5. Carry-forward and blockers

| ID | Carry-forward | Destination / decision trigger |
|---|---|---|
| CF-01 | Confirm real user purposes, participation motivations and competing outcomes | Phase 001 (start at 001-A); retain current open intent in [project intake](../../canonical/project/intake.md) |
| CF-02 | Decide event/group/visitor units, timing precision, observed exposure and corrections without excessive burden | Phase 002–003 concept discovery/definition; scientific method review before asserting validity |
| CF-03 | Separate contributor identity, site/context and research disclosure; define protections against sparse geographic/temporal linkage | Phase 002–005 concepts and authority; disclosure-risk qualification before any real-data release |
| CF-04 | Define age eligibility, contributor consent, visitor non-tracking, retention/withdrawal and applicable legal obligations | Concept/authority and downstream legal/operational review; **launch blocker** |
| CF-05 | Decide audience, initial geography, release eligibility, data-quality controls and operational responsibilities | Phase 001 purpose framing then concept/design and prelaunch decision; no assumption of open raw export |
| CF-06 | Validate participation demand, sampling limitations and alternative Poisson-process explanations with appropriate methodology | Phase 001 research-purpose framing; later evaluation/pilot before broad scientific claims |
| CF-07 | Evaluate engineering, identity vendor, hosting costs and production controls | Only downstream engineering after concept-design closure; not Phase 001 design authority |

Detailed open-question ownership is maintained in [000-D](000-d-treatflow-execution.md) and summarized in [canonical intake](../../canonical/project/intake.md), not copied into a second competing question register.

## 6. Phase 001 handoff

**Project:** TreatFlow, a small voluntary Halloween arrival-observation initiative seeking analyzable, safely shared timing/count and coarse context data.

**Motivation:** Community participation and curiosity about arrival processes, especially (but not limited to) Poisson-model suitability.

**Affected parties:** Observers, research consumers, operator, co-resident household members, visitors (often children), and broader community. These are **not** predefined auth roles.

**Provisional outcomes:** Low-burden contribution, interpretable observations including monitored exposure, responsible data use, exploratory analysis, modest operational complexity.

**Boundaries:** No assumed tracking or identification of individual children, no presumed publication of exact household locations, no assumed representative or Poisson-valid sample. Web-first, adult-only and initial-year choices are candidates, **not commitments**.

**Uncertainties:** Q-01–Q-12 in [000-D](000-d-treatflow-execution.md), plus unresolved empirical willingness to participate and privacy/science tradeoffs.

**Authoritative reading order:** [current project intake](../../canonical/project/intake.md) → [Phase 000 evidence index](index.md) as needed → [Phase 001 definition](../001/phase-definition.md) → [001-A start gate](../001/001-a-start-gate.md).

**Phase 001 mandate:** Evaluate whose human purposes the service serves, what improvement matters, burdens and tradeoffs, defensible success framing, and which initial assumptions should be challenged. Phase 001 may revisit Phase 000 conclusions with evidence; it must not treat candidate features or preliminary science as fixed requirements.

## 7. Final exit checks and status

- [x] All 000-A planned workstreams explicitly completed.
- [x] Every intake knowledge dimension evaluated and its uncertainty stated.
- [x] Provisional canonical meaning discoverable from the current project intake.
- [x] Actor exposure and missing observation distinctions identified.
- [x] Statistical hypothesis and alternative explanations preserved without claiming validation.
- [x] Inherited template versus actual TreatFlow execution separated.
- [x] Active README/bundle navigation and agent orientation corrected within scope.
- [x] Unresolved issues explicitly routed; prelaunch blockers distinguished from Phase 001 blockers.
- [x] No final concepts, technical architecture or implementation created.
- [x] Phase 001 can begin without this conversation's hidden context.

**Exit outcome: PASS WITH CARRY-FORWARD.**

**Lifecycle after merge:** Phase 000 **complete**, Phase 001 **001-A next eligible / not yet executed**. Implementation readiness **not ready**; execution **not started**; authorization **not yet**.
